Minimal-invasive in-vitro chemosensitivity testing
Cancer is highly diverse, and chemotherapy responses vary between patients. Chemo-scale utilises a blood sample to assess the effectiveness of chemotherapies for each individual. This personalised approach can greatly enhance the likelihood of successful therapy in specific cases and mitigate the risk of treatment failure.
ABOUT CHEMO-SCALE
Chemo-scale analyses tumour cells to offer guidance on drug efficacy and resistance for chemotherapy.
Chemo-scale is an innovative non-invasive test offering clinically relevant insights, obtained through a safe, straightforward, and swift blood draw. It delves into in vitro chemo-resistance within Circulating Tumour Associated Cells (CTACs), extracted from the blood sample. These CTACs encompass both circulating tumour cells (CTCs), originating from the tumour, and tumour-associated cells (TACs), crucial for tumour survival and growth. Detecting chemo-resistance in CTACs could signify a heightened risk of treatment failure and disease advancement.
DCG has demonstrated the clinical significance of chemo-scale through trials involving over 5,000 patients.
Through Chemo-scale analysis, we mitigate the risks of therapy failure for patients, leading to cost savings, minimising trial and error, and most importantly, intensifying the focus on attacking the patient's cancer, not the patient themselves.
Chemo-scale directly assesses the impact of chemotherapy/anti-cancer drugs on the patient's tumour cells, aiding in tailoring the treatment plan based on the sensitivity and resistance patterns of these cells.
Armed with this information, both the physician and the patient can select the most effective chemotherapy from the available options.
Chemo-scale is conducted on cells obtained from a fresh biopsy sample of the tumour or circulating tumour-associated cells (C-ETACs) isolated from peripheral blood, with a control analysis incorporated.
When analysing the chemo-sensitivity pattern of circulating tumour-associated cells and tumour tissue-derived cells from the same patient, we observed a concordance of 93.7%.
ADVANTAGES
SAMPLE REQUIREMENTS
20 ml blood in EDTA tubes
Turn Around Time (TAT):
8 - 10 days from receipt of the sample
FAQ
What is Chemo-scale?
Chemo-scale is a powerful analysis performed on live tumour cells. It reveals which drugs or combinations will kill the cancer of an individual patient more effectively.
How can chemo-scale help?
Not all drugs work the same on all patients. Some drugs may not prove beneficial for the patient and waste valuable time and resources at a critical point in treatment. With chemo-scale there is a way to know how effective the chemotherapy will be, before starting the treatment. Comparing the efficacy of chemo-resistency profile with the radiological response focussing on disease progression, we found a concordance of 87.0%.
How is Chemo-scale different from other pre-treatment cancer tests?
Commonly available molecular tests provide information mainly about targeted therapy drugs, where cytotoxic chemotherapy is the most common first therapy.
chemo-scale evaluates the actual response of cancer cells to cytotoxic chemotherapy drugs.
The key difference between other tests and chemo-scale is, we use a different approach to identify the relevant cells in a short-term culture thus enabling accurate advise.
It is clinically validated with more than 5.000 patients.
CONTACT
Cancer Profiling Australia
903/50 Clarence Street,
SYDNEY NSW 2000
PH +61 1300 282 482
FAX +61 2 8088 7097
Email: info@cancerprofiling.com.au